Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2022 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $31.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million, compared with a TTM value of $31.8 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $31.8 million, changed 0.0% over the prior year.
  • Non-Current Deffered Revenue was $31.8 million for Q4 2025 at Kiniksa Pharmaceuticals International, roughly flat from $31.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $31.8 million in Q4 2024 and bottomed at $261000.0 in Q4 2023.
  • Average Non-Current Deffered Revenue over 4 years is $17.6 million, with a median of $12.0 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 97.82% in 2023, then skyrocketed 12088.12% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $12.0 million in 2022, then crashed by 97.82% to $261000.0 in 2023, then surged by 12088.12% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for KNSA at $31.8 million in Q4 2025, $31.8 million in Q3 2025, and $31.8 million in Q2 2025.